𝙳𝚛𝚊. 𝙰𝚗𝚊 𝙻𝚊𝚞 🇲🇽

🚨 Beyond Anti-Ro/SSA: The New Biomarker Revolution in Sjögren’s Disease (2026) 🧬 30–40% of patients are SSA-negative → diagnosis remains challenging. ⚡ What’s changing? 🔹 SP1 • CA6 • PSP → earliest gland-specific antibodies 🔹 Anti-M3R → strongest functional autoantibody; blocks exocrine secretion 🔹 Anti-AQP5 → promising marker of salivary dysfunction 🔹 FNBP4 • SNRPC • CCL4 • KDM6B → next-generation biomarkers for SSA-negative SjD 🔹 12-antigen proteomic signatures → the future of precision diagnostics 🎯 Beyond diagnosis ✅ Earlier detection ✅ Seronegative SjD ✅ Disease phenotyping ✅ Organ involvement prediction ✅ Precision medicine ❗ Reality check 🚫 No novel antibody has replaced anti-Ro/SSA 🚫 None are included in the 2016 ACR/EULAR classification criteria 📈 The field is shifting from single antibodies → multiplex biomarker panels + proteomics + AI The future of Sjögren’s disease won’t be defined by one antibody—but by a molecular signature. 📚 Front Immunol. 2025 | Nat Rev Rheumatol. 2024 | RMD Open. 2026 #SjogrensDisease #Sjögrens #Autoantibodies #Rheumatology #ClinicalImmunology #PrecisionMedicine #Autoimmunity #MedTwitter #MedX #FOAMed – at Lucknow, India